Please try another search
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Douglas E. Onsi | 52 | 2011 | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director |
Christopher K. Mirabelli | 67 | 2011 | Chairman |
James H. Cavanaugh | 84 | 2016 | Independent Director |
Thomas John Dietz | 57 | 2016 | Lead Independent Director |
Joseph Loscalzo | 70 | 2016 | Independent Director |
William W. Li | 58 | 2017 | Independent Director |
Carl F. Nathan | - | - | Member of Scientific Advisory Board |
David Tuveson | - | - | Member of Scientific Advisory Board |
Nissim Mashiach | 60 | 2017 | Independent Director |
Andrew B Nixon | - | 2021 | Member of Scientific Advisory Board |
Richard B. Gaynor | 73 | 2021 | Member of Scientific Advisory Board |
Eileen M. O’Reilly | - | 2022 | Member of Scientific Advisory Board |
Richard L. Schilsky | 73 | 2022 | Independent Director |
Scott Joseph Antonia | - | 2023 | Member of Scientific Advisory Board |
Christian M. Richard | 54 | 2023 | Independent Director |
Bernard M. Fine | - | 2024 | Member of Scientific Advisory Board |
Patricia A. Martin | 63 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review